Zacks Investment Research Reiterates “Sell” Rating for Yield10 Bioscience (NASDAQ:YTEN)

Yield10 Bioscience (NASDAQ:YTEN)‘s stock had its “sell” rating restated by Zacks Investment Research in a research note issued to investors on Saturday, Zacks.com reports.

According to Zacks, “Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. “

Several other brokerages have also issued reports on YTEN. National Securities restated a “buy” rating and issued a $5.00 price objective on shares of Yield10 Bioscience in a report on Tuesday, August 20th. Aegis restated a “buy” rating and issued a $2.00 price objective on shares of Yield10 Bioscience in a report on Tuesday, August 13th.

Shares of YTEN stock traded down $0.05 on Friday, hitting $0.64. 55,457 shares of the stock traded hands, compared to its average volume of 67,712. The firm’s 50-day moving average price is $0.68 and its two-hundred day moving average price is $0.90. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.33 and a current ratio of 3.33. The stock has a market capitalization of $8.64 million, a PE ratio of -0.69 and a beta of 3.15. Yield10 Bioscience has a twelve month low of $0.50 and a twelve month high of $1.77.

Yield10 Bioscience (NASDAQ:YTEN) last announced its quarterly earnings results on Monday, August 12th. The specialty chemicals company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. The firm had revenue of $0.32 million for the quarter. Yield10 Bioscience had a negative net margin of 1,320.21% and a negative return on equity of 145.61%. On average, equities research analysts anticipate that Yield10 Bioscience will post -0.66 EPS for the current fiscal year.

A hedge fund recently raised its stake in Yield10 Bioscience stock. Renaissance Technologies LLC boosted its stake in Yield10 Bioscience Inc (NASDAQ:YTEN) by 9.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 478,176 shares of the specialty chemicals company’s stock after buying an additional 41,500 shares during the period. Renaissance Technologies LLC owned approximately 3.83% of Yield10 Bioscience worth $463,000 at the end of the most recent quarter. 7.69% of the stock is currently owned by institutional investors and hedge funds.

About Yield10 Bioscience

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.

Read More: Market Capitalization and Individual Investors

Get a free copy of the Zacks research report on Yield10 Bioscience (YTEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.